Antithrombotic Agents

Consultative Hemostasis and Thrombosis: Third Edition

Volumn , Issue , 2013, Pages 477-495

  Patriquin, Christopher ^a   Crowther, Mark ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902034808     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-2296-9.00026-9     Document Type: Chapter

References (169)

1. Hirsh J, Guyatt G, Albers GW, et al. Executive summary: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:71S-109S.
2. McCormick WP Medical-legal implications of anticoagulation. J Thromb Thrombolysis 2001, 12:95-97.
3. Warfarin and INR monitoring: are you on target? 2007, Canadian Medical Protective Association, Ottawa, pp 1-2.
4. Anticoagulant, antiplatelet agent and thrombolytic therapy: a medico-legal perspective 2009, Canadian Medical Protective Association, Ottawa, pp 1-6.
5. Di Nisio M, Middeldorp S, Buller HR Direct thrombin inhibitors. N Engl J Med 2005, 353:1028-1040.
6. Eikelboom JW, Weitz JI New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. Br Med J 2001, 342:c7270.
7. Hankey GJ, Eikelboom JW Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011, 123:1436-1450.
8. Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009, 101:77-85.
9. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342-2352.
10. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation, FDA news release 2010, US Food and Drug Administration, Silver Spring, Md.
11. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
12. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011, 124:1573-1579.
13. van Ryn J, Litzenburger T, et al: Dabigatran anticoagulant activity is safely neutralized by an antibody selective to dabigatran in in vitro and in vivo models. Paper presented at the Annual Scientific Session and Expo: Boehringer Ingelheim, 2011.
14. Giorgi MA, Cohen Arazi H, Gonzalez CD, et al. Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban. Expert Opin Pharmacother 2011, 12:567-577.
15. Walenga JM, Adiguzel C Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 2010, 64:956-967.
16. Gnoth MJ, Buetehorn U, Muenster U, et al. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharmacol Exp Ther 2011, 338:372-380.
17. Kubitza D, Becka M, Roth A, et al. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008, 24:2757-2765.
18. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008, 358:2765-2775.
19. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009, 373:1673-1680.
20. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008, 358:2776-2786.
21. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510.
22. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
23. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012, 366:9-19.
24. Gibson CM Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-Thrombolysis in Myocardial Infarction 51 Trial (ATLAS ACS 2-TIMI 51): a randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome in AHA 2011, Orlando, Florida.
25. Cohen AT, Spiro TE, Buller HR, et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis 2011, 31:407-416.
26. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005, 78:412-421.
27. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009, 361:594-604.
28. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010, 375:807-815.
29. Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010, 363:2487-2498.
30. Buller H, Deitchman D, Prins M, et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008, 6:1313-1318.
31. Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009, 119:2877-2885.
32. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
33. Kessler CM Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data?. J Thromb Haemost 2006, 4:963-966.
34. Vigue B Bench-to-bedside review: optimising emergency reversal of vitamin K antagonists in severe haemorrhage-from theory to practice. Crit Care 2009, 13:209.
35. Wittkowsky AK, Devine EB Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy 2004, 24:1311-1316.
36. Anand SS Oral anticoagulants in patients with coronary artery disease: an inexpensive and effective strategy. Thromb Res 2003, 109:159-161.
37. Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997, 126:133-136.
38. Lee A, Crowther M Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure. J Thromb Thrombolysis 2011, 31:249-258.
39. Narum S, Solhaug V, Myhr K, et al. Warfarin-associated bleeding events and concomitant use of potentially interacting medicines reported to the Norwegian spontaneous reporting system. Br J Clin Pharmacol 2011, 71:254-262.
40. de Assis MC, Rabelo ER, Avila CW, et al. Improved oral anticoagulation after a dietary vitamin K-guided strategy: a randomized controlled trial. Circulation 2009, 120:1115-1122.
41. Sconce E, Avery P, Wynne H, et al. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2007, 109:2419-2423.
42. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002, 287:1690-1698.
43. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005, 352:2285-2293.
44. Kangelaris KN, Bent S, Nussbaum RL, et al. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med 2009, 24:656-664.
45. Burmester JK, Berg RL, Yale SH, et al. A randomized controlled trial of genotype-based Coumadin initiation. Genet Med 2011, 13:509-518.
46. Gong IY, Tirona RG, Schwarz UI, et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 2011, 118:3163-3171.
47. Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 2004, 164:66-70.
48. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008, 1:84-91.
49. Lurie Y, Loebstein R, Kurnik D, et al. Warfarin and vitamin K intake in the era of pharmacogenetics. Br J Clin Pharmacol 2010, 70:164-170.
50. Raynor DK, Dickinson R, Knapp P, et al. Buyer beware? Does the information provided with herbal products available over the counter enable safe use?. BMC Med 2011, 9:94.
51. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:160S-198S.
52. Anand SS, Yusuf S Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol 2003, 41:62S-69S.
53. Baglin TP, Keeling DM, Watson HG Guidelines on oral anticoagulation (warfarin): third edition-2005 update. Br J Haematol 2006, 132:277-285.
54. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006, 151:713-719.
55. Oden A, Fahlen M Oral anticoagulation and risk of death: a medical record linkage study. Br Med J 2002, 325:1073-1075.
56. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996, 348:423-428.
57. Ayirookuzhi SJ, Chintapalli N, Gu X, et al. A gut reaction?. Am J Med 2007, 120:143-145.
58. Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:844S-886S.
59. Crowther MA, Douketis JD, Schnurr T, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 2002, 137:251-254.
60. Crowther MA, Ageno W, Garcia D, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med 2009, 150:293-300.
61. Patriquin C, Crowther M Treatment of warfarin-associated coagulopathy with vitamin K. Expert Rev Hematol 2011, 4:657-667.
62. Garcia D, Crowther MA, Ageno W Practical management of coagulopathy associated with warfarin. Br Med J 2010, 340:c1813.
63. Holland L, Warkentin TE, Refaai M, et al. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion 2009, 49:1171-1177.
64. Tran H, Collecutt M, Whitehead S, et al. Prothrombin complex concentrates used alone in urgent reversal of warfarin anticoagulation. Intern Med J 2011, 41:337-343.
65. Linkins LA, Choi PT, Douketis JD Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003, 139:893-900.
66. Weitz JI Low-molecular-weight heparins. N Engl J Med 1997, 337:688-698.
67. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990, 86:385-391.
68. Bernardi E, Piccioli A, Oliboni G, et al. Nomograms for the administration of unfractionated heparin in the initial treatment of acute thromboembolism-an overview. Thromb Haemost 2000, 84:22-26.
69. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med 1993, 119:874-881.
70. Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991, 151:333-337.
71. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999, 34:890-911.
72. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2000, 36:970-1062.
73. King CS, Holley AB, Jackson JL, et al. Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: a metaanalysis. Chest 2007, 131:507-516.
74. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:381S-453S.
75. Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994, 154:49-56.
76. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:340S-380S.
77. Rosenberg AF, Zumberg M, Taylor L, et al. The use of anti-Xa assay to monitor intravenous unfractionated heparin therapy. J Pharm Pract 2011, 23:210-216.
78. Baker BA, Adelman MD, Smith PA, et al. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays. Arch Intern Med 1997, 157:2475-2479.
79. Rosborough TK Monitoring unfractionated heparin therapy with antifactor Xa activity results in fewer monitoring tests and dosage changes than monitoring with the activated partial thromboplastin time. Pharmacotherapy 1999, 19:760-766.
80. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:141S-159S.
81. Uprichard J, Manning RA, Laffan MA Monitoring heparin anticoagulation in the acute phase response. Br J Haematol 2010, 149:613-619.
82. Eikelboom JW, Hirsh J Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost 2006, 96:547-552.
83. Bucur SZ, Levy JH, Despotis GJ, et al. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion 1998, 38:481-498.
84. Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992, 152:1589-1595.
85. Kearon C, Ginsberg JS, Julian JA, et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006, 296:935-942.
86. Vardi M, Zittan E, Bitterman H Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev 2009, 4. CD006771.
87. Warkentin TE Heparin-induced skin lesions. Br J Haematol 1996, 92:494-497.
88. Warkentin TE Heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 2007, 21:589-607.
89. Warkentin TE, Sheppard JA, Sigouin CS, et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006, 108:2937-2941.
90. Dahlman TC Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993, 168:1265-1270.
91. Dahlman T, Lindvall N, Hellgren M Osteopenia in pregnancy during long-term heparin treatment: a radiological study post partum. Br J Obstet Gynaecol 1990, 97:221-228.
92. Hirsh J, Levine MN Low molecular weight heparin. Blood 1992, 79:1-17.
93. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996, 334:682-687.
94. Schraibman IG, Milne AA, Royle EM Home versus in-patient treatment for deep vein thrombosis. Nurs Times 2001, 97:35.
95. Lim W, Dentali F, Eikelboom JW, et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006, 144:673-684.
96. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, et al. Adjusted versus fixed doses of the low-molecular-weight heparin Fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group. Thromb Haemost 1994, 71:698-702.
97. Lim W Using low molecular weight heparin in special patient populations. J Thromb Thrombolysis 2010, 29:233-240.
98. Chow SL, Zammit K, West K, et al. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 2003, 43:586-590.
99. Sanderink GJ, Guimart CG, Ozoux ML, et al. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002, 105:225-231.
100. Douketis J, Cook D, Meade M, et al. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med 2008, 168:1805-1812.
101. Spinler SA, Inverso SM, Cohen M, et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003, 146:33-41.
102. Borkgren-Okonek MJ, Hart RW, Pantano JE, et al. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg Obes Relat Dis 2008, 4:625-631.
103. Scholten DJ, Hoedema RM, Scholten SE A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg 2002, 12:19-24.
104. Bates SM Pregnancy-associated venous thromboembolism: prevention and treatment. Semin Hematol 2011, 48:271-284.
105. White RH, Ginsberg JS Low-molecular-weight heparins: are they all the same?. Br J Haematol 2003, 121:12-20.
106. van Dongen CJ, van den Belt AG, Prins MH, et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004, 4. CD001100 Oct 18.
107. Erkens PM, Prins MH Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2010, 9. CD001100 Sept 8.
108. Othieno R, Abu Affan M, Okpo E Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev 2007, 3. CD003076 Jul 18.
109. Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 2011, 378:41-48.
110. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003, 349:146-153.
111. Akl EA, Barba M, Rohilla S, et al. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2008, 2. CD006650 Apr 16.
112. Akl EA, Rohilla S, Barba M, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2008, 1. CD006649 Jan 23.
113. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004, 22:1944-1948.
114. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007, 50:e1-e157.
115. Singh S, Bahekar A, Molnar J, et al. Adjunctive low molecular weight heparin during fibrinolytic therapy in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. Clin Cardiol 2009, 32:358-364.
116. Murphy SA, Gibson CM, Morrow DA, et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 2007, 28:2077-2086.
117. Koch A, Bouges S, Ziegler S, et al. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: update of previous meta-analyses. Br J Surg 1997, 84:750-759.
118. Greer IA, Nelson-Piercy C Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005, 106:401-407.
119. Mahe I, Aghassarian M, Drouet L, et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 2007, 97:581-586.
120. Martel N, Lee J, Wells PS Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005, 106:2710-2715.
121. Prandoni P, Siragusa S, Girolami B, et al. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 2005, 106:3049-3054.
122. Levi M, Eerenberg ES, Kampuisen PW Anticoagulants. Old and new. Hamostaseologie 2011, 31:229-235.
123. Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002, 359:1715-1720.
124. Gallus AS, Coghlan DW Heparin pentasaccharide. Curr Opin Hematol 2002, 9:422-429.
125. Paolucci F, Frasa H, Van Aarle F, et al. Two sensitive and rapid chromogenic assays of fondaparinux sodium (Arixtra) in human plasma and other biological matrices. Clin Lab 2003, 49:451-460.
126. Turpie AG, Eriksson BI, Lassen MR, et al. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. J South Orthop Assoc 2002, 11:182-188.
127. Agnelli G, Bergqvist D, Cohen AT, et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005, 92:1212-1220.
128. Turpie A, Bauer K, Eriksson B, et al. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration. Thromb Haemost 2003, 90:364-366.
129. Eikelboom JW, Quinlan DJ, O'Donnell M Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation 2009, 120:2006-2011.
130. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004, 140:867-873.
131. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003, 349:1695-1702.
132. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005, 106:3791-3796.
133. Kuo KH, Kovacs MJ Fondaparinux: a potential new therapy for HIT. Hematology 2005, 10:271-275.
134. Warkentin TE, Davidson BL, Buller HR, et al. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest 2011, 140:366-373.
135. Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs. enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002, 162:1833-1840.
136. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002, 106:2550-2554.
137. Bijsterveld NR, Vink R, van Aken BE, et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol 2004, 124:653-658.
138. Paty I, Trellu M, Destors JM, et al. Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost 2010, 8:722-729.
139. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation 1999, 100:587-593.
140. Fischer KG, Liebe V, Hudek R, et al. Anti-hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin. Thromb Haemost 2003, 89:973-982.
141. Greinacher A, Eichler P, Albrecht D, et al. Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. Blood 2003, 101:2617-2619.
142. Dettke M, Jurko S, Ruger BM, et al. Increased serum flt3-ligand in healthy donors undergoing granulocyte colony-stimulating factor-induced peripheral stem cell mobilization. J Hematother Stem Cell Res 2001, 10:317-320.
143. Warkentin TE, Greinacher A, Koster A Bivalirudin. Thromb Haemost 2008, 99:830-839.
144. Lopes RD, Alexander KP, Manoukian SV, et al. Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009, 53:1021-1030.
145. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008, 358:2218-2230.
146. Kiser TH, Fish DN Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy 2006, 26:452-460.
147. Warkentin TE Agents for the treatment of heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 2010, 24:755-775.
148. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995, 333:764-769.
149. Eichler P, Lubenow N, Strobel U, et al. Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin. Blood 2004, 103:613-616.
150. Koster A, Chew D, Grundel M, et al. An assessment of different filter systems for extracorporeal elimination of bivalirudin: an in vitro study. Anesth Analg 2003, 96:1316-1319.
151. Swan SK, Hursting MJ The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000, 20:318-329.
152. Levine RL, Hursting MJ, McCollum D Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 2006, 129:1167-1175.
153. Beiderlinden M, Treschan TA, Gorlinger K, et al. Argatroban anticoagulation in critically ill patients. Ann Pharmacother 2007, 41:749-754.
154. Argatroban for treatment of heparin-induced thrombocytopenia. Med Lett Drugs Ther 2001, 43:11-12.
155. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001, 103:1838-1843.
156. Lewis BE, Wallis DE, Hursting MJ, et al. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 2006, 129:1407-1416.
157. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003, 163:1849-1856.
158. Matthai WH Safety and efficacy of argatroban in patients with heparin-induced thrombocytopenia. Curr Hematol Rep 2006, 5:95-99.
159. Jang IK, Brown DF, Giugliano RP, et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: Myocardial Infarction with Novastan and TPA (MINT) study. J Am Coll Cardiol 1999, 33:1879-1885.
160. Argatroban drug information, Lexicomp Online (website), 1978-2011.
161. Danhof M, de Boer A, Magnani HN, et al. Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis 1992, 22:73-84.
162. Krauel K, Furll B, Warkentin TE, et al. Heparin-induced thrombocytopenia-therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. J Thromb Haemost 2008, 6:2160-2167.
163. Chong BH Low molecular weight heparinoid and heparin-induced thrombocytopenia (abstract). Aust N Z J Med 1996, 26:331.
164. Wilhelm MJ, Schmid C, Kececioglu D, et al. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172. Ann Thorac Surg 1996, 61:920-924.
165. Gillis S, Merin G, Zahger D, et al. Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia. Br J Haematol 1997, 98:657-659.
166. Sodian R, Loebe M, Gorman KF, et al. Heparin induced thrombocytopenia. Experiences in 12 heart surgery patients. ASAIO J 1997, 43:M430-M433.
167. Farner B, Eichler P, Kroll H, et al. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001, 85:950-957.
168. Lubenow N, Warkentin TE, Greinacher A, et al. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. Thromb Res 2006, 117:507-515.
169. Ibbotson T, Perry CM Danaparoid: a review of its use in thromboembolic and coagulation disorders. Drugs 2002, 62:2283-2314.